Several studies sponsored by Invitae underscore the importance of genetic testing for improving cancer outcomes, according to the company. These data will be presented at the 2022 ASCO annual meeting.
Several ongoing trials demonstrate that CPI-613 (devimistat) is a potential treatment for pancreatic cancer, clear cell sarcoma, and biliary tract cancer.
Updated data have emerged from the ELAINE-2 clinical trial of lasofoxifene plus abemaciclib in women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.
Researchers from the SWOG Cancer Research Network used methylation patterns in cell-free DNA extracted from blood samples to predict which patients with muscle-invasive bladder cancer were likely to benefit from chemotherapy before their surgery.
Researchers from Roswell Park Comprehensive Cancer Center uncovered a previously unknown function of a gene that regulates the p53 protein, mutations of which have been linked to a wide variety of cancers.
Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found that vascular endothelial growth factor-A (VEGF-A)—a potent cytokine—can increase expression of dopamine D2 receptors on endothelial cells.
Scientists at Yale Cancer Center found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.
Using single-cell analysis, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found that previously identified subtypes for colorectal cancer may not offer nuanced tumor classification.
Research from Cedars-Sinai Cancer showed that a combination of androgen deprivation therapy plus pelvic lymph node radiation kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years.
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, according to a large epidemiologic study led by NCI researchers.
